
Lilly Unveils First Clinical Data for Next-Gen FRα ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025
Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data for its investigational folate receptor alpha (FRα) targeting antibody-drug conjugate…













